TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 30, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 03, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
April 25, 2023 07:41 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 08, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
February 28, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
December 27, 2022 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
December 14, 2022 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold Enrollment Continues Ahead of Schedule; Next Interim Analysis...
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
November 21, 2022 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...